{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:49:46Z","timestamp":1791143386764,"version":"4.1.0"},"reference-count":230,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10410"],"award-info":[{"award-number":["24K10410"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cyclodextrins (CyDs) are cyclic oligosaccharides that form inclusion complexes that allow organic compounds and other substances to be incorporated into their cavities. Hydroxypropyl-\u03b2-cyclodextrin (HP-\u03b2-CyD) is frequently used to improve the formulation properties of poorly water-soluble drugs because of its aqueous solubility and biocompatibility. Previous studies have demonstrated that the solubility and biocompatibility of poorly water-soluble anti-cancer agents can be improved by complexation with HP-\u03b2-CyD, which in some cases enhances their anticancer activity relative to the unmodified drugs. Advances in formulation strategies have enabled more efficient intracellular delivery, improved tissue and cell selectivity, and controlled release. HP-\u03b2-CyD has also been investigated as an active pharmaceutical ingredient, with demonstrated efficiency in treating leukemia and breast cancer. For example, folate-conjugated HP-\u03b2-CyD exhibits high selectivity for folate receptor-expressing cells and more potent anti-cancer activity than unmodified HP-\u03b2-CyD. Autophagy has been suggested to be involved in this mechanism. The continued development of drug-delivery systems that integrate advanced technologies and materials based on HP-\u03b2-CyD holds promise for further advances in cancer therapy. These findings indicate a paradigm shift in the role of HP-\u03b2-CyD from a formulation additive to an active pharmaceutical ingredient, suggesting broader applications for HP-\u03b2-CyD in anticancer treatments.<\/jats:p>","DOI":"10.3390\/ijms27020915","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:27:53Z","timestamp":1768570073000},"page":"915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enhancing the Water Solubility and Efficacy of Anticancer Drugs Using Hydroxypropyl-\u03b2-Cyclodextrin"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-1362","authenticated-orcid":false,"given":"Yasushi","family":"Kubota","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Saga-Ken Medical Centre Koseikan, Saga 840-8571, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nrd1576","article-title":"Cyclodextrin-based pharmaceutics: Past, present and future","volume":"3","author":"Davis","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1021\/cr970025p","article-title":"Cyclodextrin Drug Carrier Systems","volume":"98","author":"Uekama","year":"1998","journal-title":"Chem. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-409X(98)00092-1","article-title":"Highly soluble cyclodextrin derivatives: Chemistry, properties, and trends in development","volume":"36","author":"Szente","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dahabra, L., Broadberry, G., Le Gresley, A., Najlah, M., and Khoder, M. (2021). Sunscreens Containing Cyclodextrin Inclusion Com plexes for Enhanced Efficiency: A Strategy for Skin Cancer Prevention. Molecules, 26.","DOI":"10.3390\/molecules26061698"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0024-3205(88)90150-6","article-title":"Drug solubilizers to aid pharmacologists: Amorphous cyclodextrin derivatives","volume":"43","author":"Pitha","year":"1988","journal-title":"Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2012.06.055","article-title":"Cyclodextrins","volume":"453","author":"Kurkov","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bcpt.12917","article-title":"Cyclodextrin-Based Formulations: A Non-Invasive Platform for Targeted Drug Delivery","volume":"122","author":"Muankaew","year":"2018","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","article-title":"2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): A toxicology review","volume":"43","author":"Gould","year":"2005","journal-title":"Food Chem. Toxicol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"143697","DOI":"10.1016\/j.ijbiomac.2025.143697","article-title":"Cyclodextrins as non-viral vectors in cancer theranostics: A review","volume":"313","author":"Qu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kfoury, M., Landy, D., and Fourmentin, S. (2018). Characterization of Cyclodextrin\/Volatile Inclusion Complexes: A Review. Molecules, 23.","DOI":"10.3390\/molecules23051204"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"132467","DOI":"10.1016\/j.foodchem.2022.132467","article-title":"Cyclodextrins inclusion complex: Preparation methods, analytical techniques and food industry applications","volume":"384","author":"Rakmai","year":"2022","journal-title":"Food Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/cr970022c","article-title":"Introduction and General Overview of Cyclodextrin Chemistry","volume":"98","author":"Szejtli","year":"1998","journal-title":"Chem. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Saokham, P., Muankaew, C., Jansook, P., and Loftsson, T. (2018). Solubility of Cyclodextrins and Drug\/Cyclodextrin Complexes. Molecules, 23.","DOI":"10.3390\/molecules23051161"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Braga, S.S. (2019). Cyclodextrins: Emerging Medicines of the New Millennium. Biomolecules, 9.","DOI":"10.3390\/biom9120801"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1073\/pnas.0810895106","article-title":"Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-\/- mouse","volume":"106","author":"Liu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Davidson, C.D., Ali, N.F., Micsenyi, M.C., Stephney, G., Renault, S., Dobrenis, K., Ory, D.S., Vanier, M.T., and Walkley, S.U. (2009). Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006951"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"276ra226","DOI":"10.1126\/scitranslmed.3010101","article-title":"Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease","volume":"7","author":"Vite","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/S0140-6736(17)31465-4","article-title":"Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: A non-randomised, open-label, phase 1-2 trial","volume":"390","author":"Ory","year":"2017","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ymgme.2022.10.004","article-title":"Intravenous 2-hydroxypropyl-\u03b2-cyclodextrin (Trappsol\u00ae Cyclo\u2122) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial","volume":"137","author":"Hastings","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_22","first-page":"100988","article-title":"Long-term administration of intravenous Trappsol\u00ae Cyclo\u2122 (HP-\u03b2-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I\/II trial","volume":"36","author":"Sharma","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molmed.2024.11.011","article-title":"Treating Niemann-Pick C lysosomal storage: Approved and emerging approaches","volume":"31","author":"Klein","year":"2025","journal-title":"Trends Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lin, Y.C., Hu, S.C., Huang, P.H., Lin, T.C., and Yen, F.L. (2020). Electrospun Resveratrol-Loaded Polyvinylpyrrolidone\/Cyclodextrin Nanofibers and Their Biomedical Applications. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060552"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/10610270802596403","article-title":"Theoretical and experimental study of the inclusion complexes of ferulic acid with cyclodextrins","volume":"21","author":"Zhang","year":"2009","journal-title":"Supramol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.foodchem.2010.07.080","article-title":"Characterisation of inclusion complex of trans-ferulic acid and hydroxypropyl-\u03b2-cyclodextrin","volume":"124","author":"Wang","year":"2011","journal-title":"Food Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.colsurfb.2019.04.020","article-title":"Characterization of in vitro and in vivo bioactivity of a ferulic acid-2-Hydroxypropyl-\u03b2-cyclodextrin inclusion complex","volume":"180","author":"Hsu","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.foodchem.2009.05.061","article-title":"Effect of HP-\u03b2-cyclodextrins complexation on the antioxidant activity of flavonols","volume":"118","author":"Fortea","year":"2010","journal-title":"Food Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.phrs.2015.08.021","article-title":"The effects of baicalein and baicalin on mitochondrial function and dynamics: A review","volume":"100","author":"Nabavi","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kim, H., Yiluo, H., Park, S., Lee, J.Y., Cho, E., and Jung, S. (2016). Characterization and Enhanced Antioxidant Activity of the Cysteinyl \u03b2-Cyclodextrin-Baicalein Inclusion Complex. Molecules, 21.","DOI":"10.3390\/molecules21060703"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10847-019-00970-2","article-title":"Preparation and characterization of baicalein\/hydroxypropyl-\u03b2- cyclodextrin inclusion complex for enhancement of solubility, antioxidant activity and antibacterial activity using supercritical antisolvent technology","volume":"96","author":"Yan","year":"2019","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.saa.2006.07.006","article-title":"Complexation of quercetin with three kinds of cyclodextrins: An antioxidant study","volume":"67","author":"Jullian","year":"2007","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Haddad, R., Alrabadi, N., Altaani, B., and Li, T. (2022). Paclitaxel Drug Delivery Systems: Focus on Nanocrystals\u2019 Surface Modifications. Polymers, 14.","DOI":"10.3390\/polym14040658"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0008-6215(01)00178-1","article-title":"Investigation of inclusion complexation of paclitaxel by cyclohenicosakis-(1-->2)-(beta-D-glucopyranosyl), by cyclic-(1-->2)-beta-D-glucans (cyclosophoraoses), and by cyclomaltoheptaoses (beta-cyclodextrins)","volume":"334","author":"Lee","year":"2001","journal-title":"Carbohydr. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejps.2009.09.010","article-title":"Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel","volume":"38","author":"Vauthier","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2010.03.012","article-title":"Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles","volume":"145","author":"Zabaleta","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejps.2008.04.005","article-title":"P-glycoprotein inhibition by membrane cholesterol modulation","volume":"34","author":"Fenyvesi","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1271\/bbb.69.246","article-title":"Interaction of modified cyclodextrins with cytochrome P-450","volume":"69","author":"Ishikawa","year":"2005","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/jps.24354","article-title":"Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles","volume":"104","author":"Calleja","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3892\/ijmm.2012.1086","article-title":"Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-\u03b2-cyclodextrin as an oral delivery system","volume":"30","author":"Baek","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.2042-7158.2012.01578.x","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells","volume":"65","author":"Baek","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_42","first-page":"5397","article-title":"Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-\u03b2-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection","volume":"10","author":"Baek","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s12272-016-0753-5","article-title":"Stability of paclitaxel-loaded solid lipid nanoparticles in the presence of 2-hydoxypropyl-\u03b2-cyclodextrin","volume":"39","author":"Baek","year":"2016","journal-title":"Arch Pharm Res"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3835(98)00280-8","article-title":"The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line","volume":"135","author":"Huang","year":"1999","journal-title":"Cancer Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijpharm.2014.12.018","article-title":"Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles","volume":"478","author":"Baek","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.msec.2015.12.098","article-title":"Hydroxypropyl-\u03b2-cyclodextrin-graphene oxide conjugates: Carriers for anti-cancer drugs","volume":"61","author":"Tan","year":"2016","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.2147\/IJN.S107345","article-title":"Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs","volume":"11","author":"Li","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_48","first-page":"4387","article-title":"Thermosensitive liposomal drug delivery systems: State of the art review","volume":"9","author":"Kneidl","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_49","first-page":"4225","article-title":"Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomes","volume":"10","author":"Xu","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/08982104.2019.1579838","article-title":"Paclitaxel\/hydroxypropyl-\u03b2-cyclodextrin complex-loaded liposomes for overcoming multidrug resistance in cancer chemotherapy","volume":"30","author":"Shen","year":"2020","journal-title":"J. Liposome Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.2147\/DDDT.S314361","article-title":"Effect of a 2-HP-\u03b2-Cyclodextrin Formulation on the Biological Transport and Delivery of Chemotherapeutic PLGA Nanoparticles","volume":"15","author":"Zheng","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"132268","DOI":"10.1016\/j.ijbiomac.2024.132268","article-title":"Preparation, characterization and evaluation of HP\u03b2CD-PTX\/PHB nanoparticles for pH-responsive, cytotoxic and apoptotic properties","volume":"270","author":"Aslam","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/nnm.15.73","article-title":"Developing nanocrystals for cancer treatment","volume":"10","author":"Lu","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ddr.21452","article-title":"Cyclodextrin complexes: Perspective from drug delivery and formulation","volume":"79","author":"Jacob","year":"2018","journal-title":"Drug Dev. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"101607","DOI":"10.1016\/j.jddst.2020.101607","article-title":"Mechanisms for oral absorption enhancement of drugs by nanocrystals","volume":"56","author":"Liu","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1208\/s12249-022-02373-y","article-title":"Hydroxypropyl Beta Cyclodextrin as a Potential Surface Modifier for Paclitaxel Nanocrystals","volume":"23","author":"Haddad","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.carbpol.2019.04.024","article-title":"Biotin and arginine modified hydroxypropyl-\u03b2-cyclodextrin nanoparticles as novel drug delivery systems for paclitaxel","volume":"216","author":"Yan","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"114654","DOI":"10.1016\/j.colsurfb.2025.114654","article-title":"Functionalized hydroxypropyl-\u03b2-cyclodextrin inclusion complex for combined tumor therapy through intelligent delivery of paclitaxel and polarization of M2-like tumor associated macrophages","volume":"252","author":"Fu","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.apsb.2018.07.008","article-title":"Recent developments in topoisomerase-targeted cancer chemotherapy","volume":"8","author":"Hevener","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Venkatachalam, A., and Kaufmann, S.H. (2025). Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future. J. Mol. Biol., 169401.","DOI":"10.1016\/j.jmb.2025.169401"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"109040","DOI":"10.1016\/j.bioorg.2025.109040","article-title":"Recent progress in topoisomerase inhibitors as anticancer agents: Research and design strategies for Topo I and II inhibitors via structural optimization","volume":"165","author":"Shen","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.biomaterials.2004.06.013","article-title":"A novel non-toxic camptothecin formulation for cancer chemotherapy","volume":"26","author":"Berrada","year":"2005","journal-title":"Biomaterials"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Ruiz, V., Cores, \u00c1., Mart\u00edn-C\u00e1mara, O., Orellana, K., Cervera-Carrasc\u00f3n, V., Michalska, P., Olives, A.I., Le\u00f3n, R., Mart\u00edn, M.A., and Men\u00e9ndez, J.C. (2021). Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101609"},{"key":"ref_64","first-page":"81","article-title":"Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan)","volume":"20","author":"Giovanella","year":"2002","journal-title":"Int. J. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijpharm.2010.07.012","article-title":"Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: In vitro and in vivo evaluation","volume":"397","author":"Jiang","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijpharm.2011.05.056","article-title":"Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-\u03b2-cyclodextrin and safety evaluation","volume":"415","author":"Jiang","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2015.05.047","article-title":"Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor","volume":"490","author":"Chen","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.18632\/aging.101144","article-title":"TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin","volume":"8","author":"Uzor","year":"2016","journal-title":"Aging"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Coisne, C., Tilloy, S., Monflier, E., Wils, D., Fenart, L., and Gosselet, F. (2016). Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases. Molecules, 21.","DOI":"10.3390\/molecules21121748"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mcn.2017.11.014","article-title":"Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy","volume":"86","author":"Uzor","year":"2018","journal-title":"Mol. Cell Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"116609","DOI":"10.1016\/j.taap.2023.116609","article-title":"d-Limonene complexed with cyclodextrin attenuates cardiac arrhythmias in an experimental model of doxorubicin-induced cardiotoxicity: Possible involvement of calcium\/calmodulin-dependent protein kinase type II","volume":"474","author":"Souza","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"111580","DOI":"10.1016\/j.cbi.2025.111580","article-title":"D-limonene complexed with hydroxypropyl-\u03b2-cyclodextrin prevents impaired cardiac excitation-contraction coupling by reducing oxidative stress and cardiac apoptosis in an animal model of cardiotoxicity induced by doxorubicin","volume":"418","author":"Souza","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/10717544.2018.1507058","article-title":"A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin\u22c5hydrochloride for thyroid cancer treatment In Vitro and In Vivo","volume":"25","author":"Yoo","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hyun, H., Park, M.H., Jo, G., Kim, S.Y., Chun, H.J., and Yang, D.H. (2019). Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery. Mar. Drugs, 17.","DOI":"10.3390\/md17010041"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Yoon, S.J., Moon, Y.J., Chun, H.J., and Yang, D.H. (2019). Doxorubicin\u00b7Hydrochloride\/Cisplatin-Loaded Hydrogel\/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo. Nanomaterials, 9.","DOI":"10.3390\/nano9121652"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"101728","DOI":"10.1016\/j.scp.2024.101728","article-title":"Optimization of \u03b2-cyclodextrin based ultrasound- assisted extraction: A green strategy to enhance the extraction of bioactive compounds from taro leaf byproduct","volume":"41","author":"Christou","year":"2024","journal-title":"Sustain. Chem. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.3892\/ol.2020.11839","article-title":"Polyphyllin II inhibits human bladder cancer migration and invasion by regulating EMT-associated factors and MMPs","volume":"20","author":"Niu","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"108363","DOI":"10.1016\/j.abb.2020.108363","article-title":"Activation of FOXO3 pathway is involved in polyphyllin I-induced apoptosis and cell cycle arrest in human bladder cancer cells","volume":"687","author":"Li","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"120502","DOI":"10.1016\/j.jep.2025.120502","article-title":"Targeting GRB2-Akt-SREBP1 signaling axis by saponins from Paris polyphylla Smith var. yunnanensis (Franch.) Hand.-Mazz to overcome cisplatin resistance in bladder cancer","volume":"354","author":"Liu","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1021\/acs.molpharmaceut.3c00009","article-title":"Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer","volume":"20","author":"Scully","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"25545","DOI":"10.18632\/oncotarget.25370","article-title":"Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin","volume":"9","author":"Inao","year":"2018","journal-title":"Oncotarget"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"13357","DOI":"10.2147\/OTT.S281519","article-title":"BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells","volume":"13","author":"Alhoshani","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Rodenas, M.C., Pe\u00f1as-Mart\u00ednez, J., Pardo-S\u00e1nchez, I., Zaragoza-Huesca, D., Ortega-Sabater, C., Pe\u00f1a-Garc\u00eda, J., Esp\u00edn, S., Ricote, G., Montenegro, S., and Ayala-De La Pe\u00f1a, F. (2023). Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1182925"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood.2020008017","article-title":"Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition","volume":"137","author":"Manzari","year":"2021","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.actbio.2022.04.005","article-title":"Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membrane","volume":"145","author":"Liang","year":"2022","journal-title":"Acta Biomater."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Griffin, J., Wu, Y., Mu, Q., Li, X., and Ho, R.J.Y. (2023). Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15031016"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Adamo, F.M., Silva Barcelos, E.C., De Falco, F., Dorillo, E., Rompietti, C., Sorcini, D., Stella, A., Del Papa, B., Baldoni, S., and Esposito, A. (2023). Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15143618"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1021\/acs.biomac.4c00561","article-title":"CXCR4-Mediated Codelivery of FLT3 and BCL-2 Inhibitors for Enhanced Targeted Combination Therapy of FLT3-ITD Acute Myeloid Leukemia","volume":"25","author":"Yang","year":"2024","journal-title":"Biomacromolecules"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s13346-023-01462-0","article-title":"Quality by design approach-based fabrication and evaluation of self-nanoemulsifying drug delivery system for improved delivery of venetoclax","volume":"14","author":"Rajana","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"125296","DOI":"10.1016\/j.ijpharm.2025.125296","article-title":"Crosslinked hydroxypropyl-beta-cyclodextrin nanoparticles for improved efficacy of venetoclax against triple negative breast cancer","volume":"671","author":"Chandani","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1080\/07391102.2024.2305695","article-title":"Development of venetoclax with 2-hydroxypropyl-beta-cyclodextrin inclusion complex for improved bioavailability","volume":"43","author":"Patil","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1211\/002235703765344496","article-title":"Efficacy and irritancy of enhancers on the in-vitro and in-vivo percutaneous absorption of curcumin","volume":"55","author":"Fang","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Tomeh, M.A., Hadianamrei, R., and Zhao, X. (2019). A Review of Curcumin and Its Derivatives as Anticancer Agents. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051033"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bph.13621","article-title":"Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases","volume":"174","author":"Kunnumakkara","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/17425255.2019.1650914","article-title":"Is curcumin bioavailability a problem in humans: Lessons from clinical trials","volume":"15","author":"Kunnumakkara","year":"2019","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ptr.4731","article-title":"Curcumin inhibits proliferation and induces apoptosis of human colorectal cancer cells by activating the mitochondria apoptotic pathway","volume":"27","author":"Guo","year":"2013","journal-title":"Phytother. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1940-6207.CAPR-13-0387","article-title":"Curcumin suppresses proliferation of colon cancer cells by targeting CDK2","volume":"7","author":"Lim","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2007.03.005","article-title":"Curcumin for chemoprevention of colon cancer","volume":"255","author":"Johnson","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.colsurfb.2016.09.044","article-title":"Soluble curcumin amalgamated chitosan microspheres augmented drug delivery and cytotoxicity in colon cancer cells: In vitro and in vivo study","volume":"148","author":"Jyoti","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Abdelkader, H., Fatease, A.A., Fathalla, Z., Shoman, M.E., Abou-Taleb, H.A., and Abourehab, M.A.S. (2022). Design, Preparation and Evaluation of Supramolecular Complexes with Curcumin for Enhanced Cytotoxicity in Breast Cancer Cell Lines. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112283"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.275.5297.218","article-title":"Cancer chemopreventive activity of resveratrol, a natural product derived from grapes","volume":"275","author":"Jang","year":"1997","journal-title":"Science"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2008.03.057","article-title":"Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives","volume":"269","author":"Kundu","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.oraloncology.2009.10.007","article-title":"Chemo prevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of resveratrol complexed with 2-hydroxypropyl-beta-cyclodextrin","volume":"46","author":"Berta","year":"2010","journal-title":"Oral Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Hao, X., Sun, X., Zhu, H., Xie, L., Wang, X., Jiang, N., Fu, P., and Sang, M. (2021). Hydroxypropyl-\u03b2-Cyclodextrin-Complexed Resveratrol Enhanced Antitumor Activity in a Cervical Cancer Model: In Vivo Analysis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.573909"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpba.2010.03.028","article-title":"Determination of Z-3,5,4\u2032-trimethoxystilbene in rat plasma by a simple HPLC method: Application in a pre-clinical pharmacokinetic study","volume":"53","author":"Lin","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jpba.2012.09.027","article-title":"Quantification of trans-2,6-difluoro-4\u2032-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic study","volume":"72","author":"Lin","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1007\/s00216-015-8762-7","article-title":"Determination of naturally occurring resveratrol analog trans-4,4\u2032-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study","volume":"407","author":"Chen","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1002\/jsfa.11781","article-title":"Molecular encapsulation and bioactivity of gnetol, a resveratrol analogue, for use in foods","volume":"102","author":"Conesa","year":"2022","journal-title":"J. Sci. Food Agric."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Radeva, L., Yordanov, Y., Spassova, I., Kovacheva, D., Tzankova, V., and Yoncheva, K. (2024). Double Encapsulation of Resveratrol and Doxorubicin in Composite Nanogel-An Opportunity to Reduce Cardio- and Neurotoxicity of Doxorubicin. Gels, 10.","DOI":"10.3390\/gels10110699"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12943-025-02404-9","article-title":"Application of photodynamic activation of prodrugs combined with phototherapy in tumor treatment","volume":"24","author":"Du","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1248\/cpb.42.2291","article-title":"Comparison of singlet oxygen production efficiency of C60 with other photosensitizers, based on 1268 nm emission","volume":"42","author":"Nagano","year":"1994","journal-title":"Chem Pharm. Bull."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1021\/mp200204v","article-title":"Formation of stable hydrophilic C60 nanoparticles by 2-hydroxypropyl-\u03b2-cyclodextrin","volume":"8","author":"Iohara","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/jps.23045","article-title":"Evaluation of photodynamic activity of C60\/2-hydroxypropyl-\u03b2-cyclodextrin nanoparticles","volume":"101","author":"Iohara","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"570506","DOI":"10.1155\/2014\/570506","article-title":"Potential use of C60\/2-hydroxypropyl-\u03b2-cyclodextrin nanoparticles as a new photosensitizer in the treatment of cancer","volume":"2014","author":"Altaf","year":"2014","journal-title":"Int. J. Photoenergy"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/13880209.2016.1262433","article-title":"A systematic review of the active saikosaponins and extracts isolated from Radix Bupleuri and their applications","volume":"55","author":"Yuan","year":"2017","journal-title":"Pharm. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.lfs.2004.03.008","article-title":"The proliferative inhibition and apoptotic mechanism of Saikosaponin D in human non-small cell lung cancer A549 cells","volume":"75","author":"Hsu","year":"2004","journal-title":"Life Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.intimp.2012.06.010","article-title":"Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-\u03baB signaling pathway","volume":"14","author":"Lu","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.phymed.2018.11.012","article-title":"Inclusion complex of saikosaponin-d with hydroxypropyl-\u03b2-cyclodextrin: Improved physicochemical properties and anti-skin cancer activity","volume":"57","author":"Hu","year":"2019","journal-title":"Phytomedicine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.carbpol.2013.09.035","article-title":"Inclusion complex of barbigerone with hydroxypropyl-\u03b2-cyclodextrin: Preparation and in vitro evaluation","volume":"101","author":"Qiu","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbrc.2018.09.120","article-title":"Oral administration of indole substituted dipyrido[2,3-d]pyrimidine derivative exhibits anti-tumor activity via inhibiting AKT and ERK1\/2 on hepatocellular carcinoma","volume":"505","author":"Gao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"104400","DOI":"10.1016\/j.phrs.2019.104400","article-title":"An oral 2-hydroxypropyl-\u03b2-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1\/2 in hepatocellular carcinoma","volume":"148","author":"Gao","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0304-3835(01)00382-2","article-title":"In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole","volume":"165","author":"Pourgholami","year":"2001","journal-title":"Cancer Lett."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00280-004-0927-6","article-title":"Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: In vitro and in a xenograft model of peritoneal carcinomatosis","volume":"55","author":"Pourgholami","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-05-1181","article-title":"Albendazole: A potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice","volume":"12","author":"Pourgholami","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_125","first-page":"3659","article-title":"Complexation of albendazole with hydroxypropyl-beta-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice","volume":"32","author":"Ehteda","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.bmcl.2017.01.035","article-title":"Synthesis, characterization, In Vitro SAR and in vivo evaluation of N,N\u2019bisnaphthylmethyl 2-alkyl substituted imidazolium salts against NSCLC","volume":"27","author":"DeBord","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Fenyvesi, F., Nguyen, T.L.P., Haimhoffer, \u00c1., Ruszny\u00e1k, \u00c1., Vasv\u00e1ri, G., B\u00e1cskay, I., Vecserny\u00e9s, M., Ignat, S.R., Dinescu, S., and Costache, M. (2020). Cyclodextrin Complexation Improves the Solubility and Caco-2 Permeability of Chrysin. Materials, 13.","DOI":"10.3390\/ma13163618"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2015.06.038","article-title":"Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC\/ROS\/MAPK pathways","volume":"764","author":"Noh","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.bcp.2012.07.012","article-title":"Dietary flavonoid fisetin: A novel dual inhibitor of PI3K\/Akt and mTOR for prostate cancer management","volume":"84","author":"Adhami","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1972793","DOI":"10.1155\/2016\/1972793","article-title":"Fisetin Modulates Antioxidant Enzymes and Inflammatory Factors to Inhibit Aflatoxin-B1 Induced Hepatocellular Carcinoma in Rats","volume":"2016","author":"Maurya","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/carcin\/bgn269","article-title":"A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt\/EGFR\/NF-kappaB-signaling pathways","volume":"30","author":"Suh","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11626-014-9830-6","article-title":"Fisetin induces apoptosis in human nonsmall lung cancer cells via a mitochondria-mediated pathway","volume":"51","author":"Kang","year":"2015","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Yi, C., Zhang, Y., Yu, Z., Xiao, Y., Wang, J., Qiu, H., Yu, W., Tang, R., Yuan, Y., and Guo, W. (2014). Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2\/iNOS and NF-kappaB\/p300 signaling pathways. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099943"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Chou, R.H., Hsieh, S.C., Yu, Y.L., Huang, M.H., Huang, Y.C., and Hsieh, Y.H. (2013). Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK- dependent NF-kappaB signaling pathway. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071983"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1535-7163.MCT-10-0606","article-title":"Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors","volume":"10","author":"Tripathi","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/10717544.2016.1245366","article-title":"Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HP\u03b2CD in polymeric nanoparticles","volume":"24","author":"Kadari","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/07853890.2022.2045347","article-title":"Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model","volume":"54","author":"Zhu","year":"2022","journal-title":"Ann. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1158\/1078-0432.CCR-19-0516","article-title":"Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-Induced B-Cell Acute Lymphoblastic Leukemia","volume":"25","author":"Yang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"012009","DOI":"10.1088\/1757-899X\/774\/1\/012009","article-title":"Preparation of pH-Sensitive \u03b2-Cyclodextrin Derivatives and Evaluation of Their Drug-Loading Properties","volume":"774","author":"Jiang","year":"2020","journal-title":"IOP Conf. Ser. Mater. Sci. Eng."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Dietsch, G.N., Lu, H., Yang, Y., Morishima, C., Chow, L.Q., Disis, M.L., and Hershberg, R.M. (2016). Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148764"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1208\/s12248-021-00620-x","article-title":"Employing Drug Delivery Strategies to Overcome Challenges Using TLR7\/8 Agonists for Cancer Immunotherapy","volume":"23","author":"Varshney","year":"2021","journal-title":"AAPS J."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.2147\/IJN.S450205","article-title":"Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer","volume":"19","author":"Yuan","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lfs.2016.01.039","article-title":"Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells In Vitro","volume":"147","author":"Tsaur","year":"2016","journal-title":"Life Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1248\/bpb.29.1597","article-title":"Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells","volume":"29","author":"Chang","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF02976663","article-title":"Apoptosis induction of Persicae Semen extract in human promyelocytic leukemia (HL-60) cells","volume":"26","author":"Kwon","year":"2003","journal-title":"Arch. Pharm. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/01635581.2018.1508731","article-title":"Antitumor Action of Amygdalin on Human Breast Cancer Cells by Selective Sensitization to Oxidative Stress","volume":"71","author":"Abboud","year":"2019","journal-title":"Nutr. Cancer"},{"key":"ref_148","first-page":"5156","article-title":"Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells","volume":"11","author":"Park","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Makarevi\u0107, J., Rutz, J., Juengel, E., Kaulfuss, S., Tsaur, I., Nelson, K., Pfitzenmaier, J., Haferkamp, A., and Blaheta, R.A. (2014). Amygdalin influences bladder cancer cell adhesion and invasion In Vitro. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110244"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"124293","DOI":"10.1016\/j.ijpharm.2024.124293","article-title":"Formation of amygdalin\/\u03b2-cyclodextrin derivatives inclusion complexes for anticancer activity assessment in human cervical carcinoma HeLa cell line","volume":"662","author":"Meenatchi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thi azole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","article-title":"Elderly Patients with Chronic Myeloid Leukemia Benefit from a Dasatinib Dose as Low as 20 mg","volume":"17","author":"Itamura","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Cutrignelli, A., Sanarica, F., Lopalco, A., Lopedota, A., Laquintana, V., Franco, M., Boccanegra, B., Mantuano, P., De Luca, A., and Denora, N. (2019). Dasatinib\/HP-\u03b2-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030591"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"125552","DOI":"10.1016\/j.ijpharm.2025.125552","article-title":"Controlled release of dasatinib from cyclodextrin-based inclusion complexes by mechanochemistry: A computational and experimental study","volume":"675","author":"Vrban","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_155","first-page":"115","article-title":"Spotlight on Sotorasib (AMG 510) for KRAS (G12C) Positive Non-Small Cell Lung Cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"114831","DOI":"10.1016\/j.colsurfb.2025.114831","article-title":"Biosurfactant stabilized nanosuspension of KRAS inhibitor\u2014Sotorasib (AMG-510): Systematic optimization using quality by design approach","volume":"254","author":"Patel","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3748\/wjg.v30.i21.2793","article-title":"Thymoquinone affects hypoxia-inducible factor-1\u03b1 expression in pancreatic cancer cells via HSP90 and PI3K\/AKT\/mTOR pathways","volume":"30","author":"Zhao","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"116332","DOI":"10.1016\/j.biopha.2024.116332","article-title":"Exploring MTH1 inhibitory potential of Thymoquinone and Baicalin for therapeutic targeting of breast cancer","volume":"173","author":"Taiyab","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"117123","DOI":"10.1016\/j.biopha.2024.117123","article-title":"Thymoquinone, artemisinin, and thymol attenuate proliferation of lung cancer cells as Sphingosine kinase 1 inhibitors","volume":"177","author":"Shakeel","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3892\/or.2025.8990","article-title":"Hydroxypropyl-\u03b2-cyclodextrin\/thymoquinone inclusion complex inhibits non-small cell lung cancer progression through NF-\u03baB-mediated ferroptosis","volume":"54","author":"Zheng","year":"2025","journal-title":"Oncol. Rep."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23","author":"Andre","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: Current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41419-020-2222-9","article-title":"ADT-OH, a hydrogen sulfide-releasing donor, induces apoptosis and inhibits the development of melanoma in vivo by upregulating FADD","volume":"11","author":"Cai","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"eaaz5752","DOI":"10.1126\/sciadv.aaz5752","article-title":"SQR mediates therapeutic effects of H(2)S by targeting mitochondrial electron transport to induce mitochondrial uncoupling","volume":"6","author":"Jia","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41419-024-06829-w","article-title":"ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission","volume":"15","author":"Yu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_167","first-page":"266","article-title":"A novel concept of reversing neuromuscular block: Chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host","volume":"41","author":"Bom","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/jm011107f","article-title":"Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: Synthesis and structure-activity relationships","volume":"45","author":"Adam","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00000542-200309000-00018","article-title":"Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969","volume":"99","author":"Epemolu","year":"2003","journal-title":"Anesthesiology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/00000542-200510000-00007","article-title":"First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide","volume":"103","author":"Gijsenbergh","year":"2005","journal-title":"Anesthesiology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-5-16","article-title":"Niemann-Pick disease type C","volume":"5","author":"Vanier","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nm1073","article-title":"Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone","volume":"10","author":"Griffin","year":"2004","journal-title":"Nat. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2012.11.005","article-title":"Effects of cyclodextrin in two patients with Niemann-Pick Type C disease","volume":"108","author":"Matsuo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_174","first-page":"391","article-title":"Effects of intracerebroventricular administration of 2-hydroxypropyl-\u03b2-cyclodextrin in a patient with Niemann-Pick Type C disease","volume":"1","author":"Matsuo","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10072-017-2833-9","article-title":"Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: Review of initial published cases","volume":"38","author":"Casanova","year":"2017","journal-title":"Neurol. Sci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s11011-021-00842-0","article-title":"Treatment trials in Niemann-Pick type C disease","volume":"36","author":"Sitarska","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2002-07-2283","article-title":"Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses","volume":"101","author":"Li","year":"2003","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cca.2005.10.022","article-title":"Alteration in lipid profile in patients of chronic myeloid leukemia before and after chemotherapy","volume":"366","author":"Ghalaut","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2184.2011.00758.x","article-title":"Cholesterol esters as growth regulators of lymphocytic leukaemia cells","volume":"44","author":"Mulas","year":"2011","journal-title":"Cell Prolif."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0002-9440(10)65706-9","article-title":"Lipoprotein receptors in acute myelogenous leukemia: Failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation","volume":"153","author":"Rudling","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V84.8.2689.2689","article-title":"Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells","volume":"84","author":"Vitols","year":"1994","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Brindisi, M., Fiorillo, M., Frattaruolo, L., Sotgia, F., Lisanti, M.P., and Cappello, A.R. (2020). Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERR\u03b1 Pathway. Cells, 9.","DOI":"10.3390\/cells9081819"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1016\/j.celrep.2019.05.104","article-title":"Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome","volume":"27","author":"Ehmsen","year":"2019","journal-title":"Cell Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1158\/0008-5472.CAN-19-1184","article-title":"Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism","volume":"80","author":"Dattilo","year":"2020","journal-title":"Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Beckwitt, C.H., Shiraha, K., and Wells, A. (2018). Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197422"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41416-018-0267-7","article-title":"Statins attenuate outgrowth of breast cancer metastases","volume":"119","author":"Beckwitt","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jbior.2014.10.003","article-title":"Lipid rafts as major platforms for signaling regulation in cancer","volume":"57","author":"Mollinedo","year":"2015","journal-title":"Adv. Biol. Regul."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e13167","DOI":"10.1111\/cpr.13167","article-title":"Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis","volume":"55","author":"Li","year":"2022","journal-title":"Cell Prolif."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Yokoo, M., Kubota, Y., Motoyama, K., Higashi, T., Taniyoshi, M., Tokumaru, H., Nishiyama, R., Tabe, Y., Mochinaga, S., and Sato, A. (2015). 2-Hydroxypropyl-beta-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141946"},{"key":"ref_190","first-page":"249","article-title":"Hydroxypropyl-\u03b2-cyclodextrin attenuates the epithetlial-to-mesenchymal transition via endoplasmic reticulum stress in MDA-MB-231 breast cancer cells","volume":"21","author":"Wu","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Zhao, Y., He, L., Wang, T., Zhu, L., and Yan, N. (2021). 2-Hydroxypropyl-\u03b2-cyclodextrin Regulates the Epithelial to Mesenchymal Transition in Breast Cancer Cells by Modulating Cholesterol Homeostasis and Endoplasmic Reticulum Stress. Metabolites, 11.","DOI":"10.3390\/metabo11080562"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Saha, S.T., Abdulla, N., Zininga, T., Shonhai, A., Wadee, R., and Kaur, M. (2023). 2-Hydroxypropyl-beta-cyclodextrin (HPbetaCD) as a Potential Therapeutic Agent for Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15102828"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"111168","DOI":"10.1016\/j.intimp.2023.111168","article-title":"Hydroxypropyl-beta-cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity","volume":"125","author":"Zhu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","article-title":"Functional ligands for improving anticancer drug therapy: Current status and applications to drug delivery systems","volume":"29","author":"Bajracharya","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"100370","DOI":"10.1016\/j.nanoso.2019.100370","article-title":"Active targeting drug delivery nanocarriers: Ligands","volume":"19","author":"Anarjan","year":"2019","journal-title":"Nano- Struct. Nano-Objects"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Assaraf","year":"2014","journal-title":"Drug Resist. Updat."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/srep01104","article-title":"Potential use of folate-appended methyl-beta-cyclodextrin as an anticancer agent","volume":"3","author":"Onodera","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/srep04417","article-title":"Involvement of autophagy in antitumor activity of folate-appended methyl-beta-cyclodextrin","volume":"4","author":"Onodera","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1248\/bpb.b14-00531","article-title":"Evaluation of antitumor effects of folate-conjugated methyl-beta-cyclodextrin in melanoma","volume":"38","author":"Motoyama","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.2147\/IJN.S133482","article-title":"Induction of mitophagy-mediated antitumor activity with folate-appended methyl-\u03b2-cyclodextrin","volume":"12","author":"Kameyama","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Hoshiko, T., Kubota, Y., Onodera, R., Higashi, T., Yokoo, M., Motoyama, K., and Kimura, S. (2021). Folic Acid-Appended Hydroxypropyl-beta-Cyclodextrin Exhibits Potent Antitumor Activity in Chronic Myeloid Leukemia Cells via Autophagic Cell Death. Cancers, 13.","DOI":"10.3390\/cancers13215413"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Kubota, Y., Hoshiko, T., Higashi, T., Motoyama, K., Okada, S., and Kimura, S. (2023). Folate-Appended Hydroxypropyl-beta-Cyclodextrin Induces Autophagic Cell Death in Acute Myeloid Leukemia Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316720"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Kubota, Y., and Kimura, S. (2024). Current Understanding of the Role of Autophagy in the Treatment of Myeloid Leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212219"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/cas.14379","article-title":"Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter","volume":"111","author":"Saito","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.2147\/IJN.S67146","article-title":"Reversal of multidrug resistance in MCF-7\/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-\u03b2-cyclodextrin nanocarrier","volume":"10","author":"Li","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1248\/bpb.b14-00726","article-title":"Efficacy of 2-Hydroxypropyl-\u03b2-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease","volume":"38","author":"Tanaka","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/js960213f","article-title":"Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation","volume":"86","author":"Irie","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.xphs.2020.10.026","article-title":"Cyclodextrins in Parenteral Formulations","volume":"110","author":"Loftsson","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.xphs.2019.01.004","article-title":"Cyclodextrin Reduces Intravenous Toxicity of a Model Compound","volume":"108","author":"Mantik","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0024-3205(83)90304-1","article-title":"Rescue from hypervitaminosis A or potentiation of retinoid toxicity by different modes of cyclodextrin administration","volume":"32","author":"Pitha","year":"1983","journal-title":"Life Sci."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymgme.2013.04.003","article-title":"Lung toxicity of hydroxypropyl-beta-cyclodextrin infusion","volume":"109","author":"Chien","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/PDR.0b013e3181ee4dd2","article-title":"Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life","volume":"68","author":"Ramirez","year":"2010","journal-title":"Pediatr. Res."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ymgme.2011.03.001","article-title":"Pulmonary function and pathology in hydroxypropyl-beta-cyclodextin-treated and untreated Npc1(-)\/(-) mice","volume":"103","author":"Muralidhar","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1203\/PDR.0b013e3181df4623","article-title":"2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease","volume":"68","author":"Ward","year":"2010","journal-title":"Pediatr. Res."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Crumling, M.A., Liu, L., Thomas, P.V., Benson, J., Kanicki, A., Kabara, L., Halsey, K., Dolan, D., and Duncan, R.K. (2012). Hearing loss and hair cell death in mice given the cholesterol-chelating agent hydroxypropyl-beta-cyclodextrin. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0053280"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10162-015-0528-6","article-title":"Hearing Loss and Otopathology Following Systemic and Intracerebroventricular Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin","volume":"16","author":"Cronin","year":"2015","journal-title":"J. Assoc. Res. Otolaryngol."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Crumling, M.A., King, K.A., and Duncan, R.K. (2017). Cyclodextrins and Iatrogenic Hearing Loss: New Drugs with Significant Risk. Front. Cell Neurosci., 11.","DOI":"10.3389\/fncel.2017.00355"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.reprotox.2015.05.010","article-title":"Juvenile animal testing of hydroxypro pyl-\u03b2-cyclodextrin in support of pediatric drug development","volume":"56","author":"Rhimi","year":"2015","journal-title":"Reprod. Toxicol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10847-006-9212-0","article-title":"Cyclodextrins as cosmetic delivery systems","volume":"57","author":"Centini","year":"2007","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.ajkd.2007.10.044","article-title":"Osmotic nephrosis: Acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes","volume":"51","author":"Dickenmann","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Lin, E.Y., Chen, Y.S., Li, Y.S., Chen, S.R., Lee, C.H., Huang, M.H., Chuang, H.M., Harn, H.J., Yang, H.H., and Lin, S.Z. (2020). Liposome Consolidated with Cyclodextrin Provides Prolonged Drug Retention Resulting in Increased Drug Bioavailability in Brain. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124408"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13023-019-1207-1","article-title":"Expanded access with intravenous hydroxypropyl-beta-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: A case report analysis","volume":"14","author":"Hastings","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/stem.1917","article-title":"HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells","volume":"33","author":"Soga","year":"2015","journal-title":"Stem Cells"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1111\/bph.15464","article-title":"Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C","volume":"178","author":"Yamada","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"5260976","DOI":"10.1155\/2018\/5260976","article-title":"Cyclodextrin Enhances Corneal Tolerability and Reduces Ocular Toxicity Caused by Diclofenac","volume":"2018","author":"Abdelkader","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Rassu, G., Fancello, S., Roldo, M., Malanga, M., Szente, L., Migheli, R., Gavini, E., and Giunchedi, P. (2020). Investigation of Cytotoxicity and Cell Uptake of Cationic Beta-Cyclodextrins as Valid Tools in Nasal Delivery. Pharmaceutics, 12.","DOI":"10.20944\/preprints202007.0180.v1"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13346-020-00778-5","article-title":"Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies","volume":"11","author":"Santos","year":"2021","journal-title":"Drug Deliv. Transl. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:14:44Z","timestamp":1768886084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":230,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27020915"],"URL":"https:\/\/doi.org\/10.3390\/ijms27020915","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}